Last reviewed · How we verify
GC3111B
At a glance
| Generic name | GC3111B |
|---|---|
| Sponsor | GC Biopharma Corp |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3111B CI brief — competitive landscape report
- GC3111B updates RSS · CI watch RSS
- GC Biopharma Corp portfolio CI